thyssenkrupp nucera AG & Co. KGaA (ETR:NCH2)
Germany
· Delayed Price · Currency is EUR | Market Cap | 1.05B |
| Revenue (ttm) | 730.20M |
| Net Income (ttm) | -7.40M |
| Shares Out | 126.32M |
| EPS (ttm) | -0.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 36,687 |
| Average Volume | 75,619 |
| Open | 8.25 |
| Previous Close | 8.29 |
| Day's Range | 8.06 - 8.37 |
| 52-Week Range | 7.24 - 11.90 |
| Beta | 1.06 |
| RSI | 43.23 |
| Earnings Date | May 12, 2026 |
About ETR:NCH2
thyssenkrupp nucera AG & Co. KGaA engages in the development, engineering, procurement, commissioning, and licensing of electrolysis technologies in Germany, Saudi Arabia, Sweden, the United States, and internationally. It operates through the Chlor-Alkali (CA) and Green Hydrogen (gH2) segments. The company is involved in the development, planning, and construction of new-build electrolysis plants for producing green hydrogen for industrial applications; provision of services for chlor-alkali electrolysis, such as planning and construction of n... [Read more]
Financial Performance
In fiscal year 2025, ETR:NCH2's revenue was 845.20 million, a decrease of -1.98% compared to the previous year's 862.30 million. Earnings were 4.60 million, a decrease of -59.65%.
Financial StatementsNews
thyssenkrupp nucera AG & Co. KGaA Transcript: Status update
Secured a major 300 MW green hydrogen order, raising order intake guidance and confirming strong commercial momentum. Updated guidance reflects higher project costs and a US contract termination, impacting EBIT, but the business remains stable with a robust chlor-alkali segment.
thyssenkrupp nucera AG & Co. KGaA Transcript: AGM 2026
The AGM highlighted strong financial results, strategic focus on green hydrogen and Chlor-Alkali, and robust governance. All agenda items passed with large majorities, while management addressed regulatory, market, and project risks, emphasizing innovation and international expansion.
thyssenkrupp nucera AG & Co. KGaA Earnings Call Transcript: Q1 2026
Q1 results were in line with expectations, with sales and order intake down year-on-year but profitability supported by cost control and improved project mix. The project pipeline is more focused, with major opportunities in Europe and India, and full-year guidance is confirmed.
thyssenkrupp nucera AG & Co. KGaA Earnings Call Transcript: Q4 2025
Sales reached EUR 845 million with positive EBIT of EUR 2 million, driven by record chlor-alkali performance and improved green hydrogen margins. Outlook for 2025-2026 anticipates lower sales but robust order intake, with continued focus on cost control and innovation.
thyssenkrupp nucera AG & Co. KGaA Earnings Call Transcript: Q3 2025
Sales and EBIT guidance were raised following a strong nine-month performance, with robust project execution in both core alkali and green hydrogen segments. Order intake remains subdued in green hydrogen due to project delays, but a solid backlog and new technology acquisitions support future growth.
thyssenkrupp nucera AG & Co. KGaA Earnings Call Transcript: Q2 2025
Strong sales and EBIT growth were achieved in both chlor-alkali and green hydrogen segments, with Europe leading project opportunities amid regulatory support. Financials remain robust, and guidance for the year is confirmed, though U.S. policy uncertainty poses risks.
thyssenkrupp nucera AG & Co. KGaA Earnings Call Transcript: Q1 2025
Record Q1 sales and improved profitability were driven by strong execution in both green hydrogen and chlor-alkali segments. Guidance for the year is confirmed, with Europe highlighted as the key growth region for green hydrogen, and management transitions underway.
thyssenkrupp nucera AG & Co. KGaA Earnings Call Transcript: Q4 2024
Record sales and strong order intake were driven by major green hydrogen and chlor-alkali projects, with robust financials and a solid cash position. Guidance for FY 2024-25 anticipates continued growth, though regulatory and market uncertainties remain.
thyssenkrupp nucera AG & Co. KGaA Earnings Call Transcript: Q3 2024
Record Q3 sales and strong order intake were driven by major project milestones in both AWE and chlor-alkali, but regulatory delays and market uncertainties led to the withdrawal of next year's AWE guidance. Full-year sales and EBIT guidance for 2023-2024 are confirmed.